1. bookVolume 72 (2022): Issue 1 (March 2022)
Journal Details
License
Format
Journal
First Published
28 Feb 2007
Publication timeframe
4 times per year
Languages
English
access type Open Access

Initiation of insulin therapy in patients with type 2 diabetes: An observational study

Published Online: 30 Aug 2021
Page range: 147 - 157
Accepted: 23 Mar 2021
Journal Details
License
Format
Journal
First Published
28 Feb 2007
Publication timeframe
4 times per year
Languages
English
Abstract

The aim of the study was to assess the initiation of insulin therapy in patients with type 2 diabetes using health claims data on prescription medicines. The study evaluated time to insulin initiation and prescribing patterns of other anti-diabetic medicines before and after insulin initiation. Five years after starting non-insulin antidiabetic therapy, 6.4 % of patients were prescribed insulin, which is substantially lower compared to other similar studies. Among all patients who initiated insulin therapy in 2013, 30 % did not continue any other antidiabetic therapy. However, this proportion was lowered to 20 % in 2018. Before insulin initiation in 2018, metformin was prescribed in only 67 % of patients and sulfonylureas in 78 % of patients. Moreover, metformin and sulfonylureas were discontinued after insulin initiation in 26 and 37 % of patients, resp. More attention should be paid to the continuation of oral anti-diabetics, particularly metformin, after insulin initiation.

Keywords

1. M. J. Davies, D. A. D’Alessio, J. Fradkin, W. N. Kernan, C. Mathieu, G. Mingrone, P. Rossing, A. Tsapas, D. J. Wexler and J. B. Buse, Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care 41 (2018) 2669–2701; https://doi.org/10.2337/dci18-0033 Search in Google Scholar

2. Slovenian Endocrinology Association, Slovenian Guidelines on Type 2 Diabetes Management 2016 [in Slovene]; https://endodiab.si/priporocila/smernice-za-vodenje-sladkorne-bolezni/; last access date November 30, 2020. Search in Google Scholar

3. P. Home, M. Riddle, W. T. Cefalu, C. J. Bailey, R. G. Bretzel, S. Del Prato, D. Leroith, G. Schernthaner, L. van Gaal and I. Raz, Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 37 (2014) 1499–1508; https://doi.org/10.2337/dc13-2743 Search in Google Scholar

4. M. D. Campbell, D. Babic, U. Bolcina, L. Smirčić-Duvnjak, T. Tankova, A. Mitrakou, P. Kempler and A. Janez, High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study, Acta Diabetol. 56 (2019) 1045–1049; https://doi.org/10.1007/s00592-019-01346-1 Search in Google Scholar

5. G. Goodall, E. M. Sarpong, C. Hayes and W. J. Valentine, The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study, BMC Endocr. Disord. 9 (2009) Article ID 19 (9 pages); https://doi.org/10.1186/1472-6823-9-19 Search in Google Scholar

6. T. Albreht, R. Pribaković Brinovec, D. Jošar, M. Poldrugovac, T. Kostnapfel, M. Zaletel, D. Panteli and A. Maresso, Slovenia: Health system review, Health Syst. Trans. 18 (2016) (207 pages); https://www.euro.who.int/_data/assets/pdf_file/0018/312147/HiT-Slovenia_rev3.pdf; last access date February 15, 2021. Search in Google Scholar

7. E. Chiefari, B. Arcidiacono, D. Foti and A. Brunetti, Gestational diabetes mellitus: an updated overview, J. Endocrinol. Invest. 40 (2017) 899–909; https://doi.org/10.1007/s40618-016-0607-5 Search in Google Scholar

8. O. Montvida, J. Shaw, J. J. Atherton, F. Stringer and S. K. Paul, Long-term trends in antidiabetes drug usage in the U.S.: Real-world evidence in patients newly diagnosed with type 2 diabetes, Diabetes Care 41 (2018) 69–78; https://doi.org/10.2337/dc17-1414 Search in Google Scholar

9. S. Wilkinson, I. Douglas, H. Stirnadel-Farrant, D. Fogarty, A. Pokrajac, L. Smeeth and L. Tomlinson, Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017, BMJ Open 8 (2018) e022768; https://doi.org/10.1136/bmjopen-2018-022768 Search in Google Scholar

10. M. Sharma, I. Nazareth and I. Petersen, Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study, BMJ Open 6 (2016) e010210; https://doi.org/10.1136/bmjopen-2015-010210 Search in Google Scholar

11. A. Ringborg, P. Lindgren, D. D. Yin, M. Martinell and J. Stalhammar, Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes, Diabetes Metab. 36 (2010) 198–203; https://doi.org/10.1016/j.diabet.2009.11.006 Search in Google Scholar

12. F. Persson, J. Bodegard, J. T. Lahtela, T. Nystrom, M. E. Jorgensen, M. L. Jensen, H. L. Gulseth, M. Thuresson, F. Hoti, D. Nathanson, A. Norhammar, K. I. Birkeland, J. G. Eriksson and J. W. Eriksson, Different patterns of second-line treatment in type 2 diabetes after metformin mono-therapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study, Endocrinol. Diabetes Metab. 1 (2018) e00036; https://doi.org/10.1002/edm2.36 Search in Google Scholar

13. K. Kostev and W. Rathmann, Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010), Prim. Care Diabetes 7 (2013) 229–233; https://doi.org/10.1016/j.pcd.2013.03.003 Search in Google Scholar

14. J. M. van den Heuvel, N. Farzan, M. van Hoek, A.-H. Maitland-van der Zee and F. Ahmadizar, Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands, BMJ Open Diabetes Res. Care 8 (2020) e000767; https://doi.org/10.1136/bmjdrc-2019-000767 Search in Google Scholar

15. T. Wilke, N. Picker, S. Mueller, S. Geier, J. Foersch, J. Aberle, S. Martin, M. Riedl and M. Gabler, Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage, Diabetes Metab. Syndr. Obes. 12 (2019) 1225–1237; https://doi.org/10.2147/DMSO.S214288 Search in Google Scholar

16. Y. Xu, S. J. Pilla, G. C. Alexander and I. B. Murimi, Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study, PLoS One 14 (2019) e0211820; https://doi.org/10.1371/journal.pone.0211820 Search in Google Scholar

17. K. Khunti, T. Damci, L. Meneghini, C. Y. Pan and J.-F. Yale, Study of once daily levemir (SOLVETM): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice, Diabetes Obes. Metab. 14 (2012) 654–661; https://doi.org/10.1111/j.1463-1326.2012.01602.x Search in Google Scholar

18. D. C. Beachler, G. Fernandes, G. Deshpande, J. Jemison, L. G. Lyons, S. Lanes, J. Liu and A. Mc-Neill, Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a large commercial database, Curr. Med. Res. Opin. 34 (2018) 1061–1069; https://doi.org/10.1080/03007995.2017.1416348 Search in Google Scholar

19. K. Khunti, M. B. Gomes, S. Pocock, M. V. Shestakova, S. Pintat, P. Fenici, N. Hammar and J. Medina, Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review, Diabetes Obes. Metab. 20 (2018) 427–437; https://doi.org/10.1111/dom.13088 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo